- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT04762901
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
LCI-BRE-MTN-NIR-001: A Phase I Study of Niraparib in Combination With Standard Chemotherapy in Metastatic Triple-Negative Breast Cancer
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Tanulmány típusa
Fázis
- 1. fázis
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria
Subject must meet all of the following applicable inclusion criteria to participate in this study:
- Able to understand and willing to provide written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
- Male or female and age ≥ 18 years at the time of consent.
- ECOG Performance Status of 0, 1 or 2 (Stage 1), or 0-1 (Stage 2) within 14 days prior to day 1 of treatment.
Histologically or cytologically confirmed hormone receptor negative tumor (estrogen and progesterone) on pathology immunohistochemistry (IHC) assessment defined as <10% staining and HER2-negative, non-overexpressing defined by an IHC 0 or 1+ or fluorescence in-situ hybridization (FISH) HER2:CEP17 ratio < 2.0 with an average HER2 gene copy number of <4 signals/nucleus, and:
Stage 1 (metastatic):
a. Measurable (by RECIST v1.1) or evaluable lesions
Stage 2 (non-metastatic, treatment naïve, with no prior excisional biopsy/lumpectomy/LND staging):
- Primary tumor size ≥ 2 cm by at least one radiographic or clinical measurement. NOTE: this requirement does not apply to subjects with inflammatory TNBC.
- Clinical stage at presentation: cT1c-cT4, cN0-cN3
Tumor tissue:
Stage 1:
Willing to provide tumor tissue for research purposes. Fresh biopsy of metastatic lesion prior to day 1 of treatment preferred if feasible. If fresh biopsy of metastatic lesion is not feasible, fresh biopsy can be obtained from the primary tumor site (i.e. breast). Tumor tissue from bone metastases is not acceptable. If fresh biopsy from metastatic tumor or primary tumor site is not possible, archival tumor tissue (formalin-fixed paraffin embedded [FFPE] or tumor block) may be used as long as it is from within 12 months of study entry. NOTE: If tissue is not available within required timeframe (i.e., either fresh or archival) subject will still be eligible for trial.
Stage 2:
Willing to undergo fresh biopsy of the primary tumor prior to day 1 of treatment for research purposes (breast is preferred; lymph node is acceptable). If not clinically feasible, then provide archived tumor tissue (FFPE or tumor block) of the primary tumor within 12 months of study entry. If archived tissue will be submitted rather than fresh biopsy, the archived tissue must be assessed and documented by pathology to ensure adequate tumor is present for correlative analysis. NOTE: For subjects who do not have archival tumor tissue available within required timeframe or if archival tissue insufficient, a pre-treatment core biopsy of the primary breast tumor must be obtained. If subjects have inflammatory breast cancer and a core biopsy is not possible, consideration can be given to obtain a skin punch biopsy.
Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 14 days prior to day 1 of treatment.
- Absolute Neutrophil Count (ANC): greater than or equal to 1,000/µL
- Platelet Count greater than or equal to 100,000/µL without platelet transfusion within 4 weeks of day 1 of treatment
- Hemoglobin (Hgb): greater than or equal to 9 g/dL without red blood cell transfusion within 4 weeks of day 1 of treatment
- Serum creatinine (SCr): less than or equal to 1.5 × upper limit of normal (ULN)
- For subjects anticipated to receive anthracyclines, adequate cardiac function as defined by ≥50% Left Ventricular Ejection Fraction (LVEF) by ECHO or MUGA within 28 days prior to day 1 of treatment.
- Females of childbearing potential (FCBP) must have a negative serum pregnancy test within 7 days prior to day 1 of treatment and documented. NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or are postmenopausal (>45 years of age and at least 12 consecutive months with no menses without an alternative medical cause).
FCBP must be willing to use a highly effective contraceptive method (i.e., highly effective achieves a failure rate of <1% per year when used consistently and correctly) or a combination method from the time of informed consent until 30 days after treatment discontinuation. Contraceptive methods with low user dependency are preferable but not required.
Acceptable methods of contraception (highly effective) are:
Single method (one of the following is acceptable):
- Non-hormonal Intrauterine device (IUD)
- Vasectomy of a female subject's partner
- Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments.
Combination method (requires use of two of the following):
- Diaphragm with spermicide (Cannot be used in conjunction with cervical cap/spermicide)
- Cervical cap with spermicide (nulliparous women only)
- Contraceptive sponge with spermicide (nulliparous women only)
- Male condom or female condom (cannot be used together) with spermicide
- Male subjects with female partners who are of child-bearing potential, should use a highly effective method of contraception during niraparib therapy and for 90 days after receiving the last dose of niraparib.
- Subjects must agree to not donate blood for 90 days after receiving the last dose of niraparib.
- Female subjects must agree to not breastfeed during the study or for 30 days after the last dose of study treatment and male subjects must not donate sperm during niraparib therapy and for 90 days after receiving the last dose of niraparib.
- As determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study.
- Ability to swallow oral medications.
Stage 1 Exclusion Criteria
Subjects meeting any of the criteria below may not participate in Stage 1 of the study:
- Subject has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Note: Subjects with previously treated brain metastases may participate if there is no evidence of disease progression for at least 4 weeks after CNS-directed treatment as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period, are asymptomatic, have no requirement for steroids, no requirement for anticonvulsants, and stable CNS radiographic study showing no significant vasogenic edema ≥ 4 weeks since completion of radiation and ≥ 1 week since discontinuation of steroids. Carcinomatous meningitis precludes a subject from study participation regardless of clinical stability.
- More than 3 prior lines of chemotherapy for triple-negative metastatic disease.
- Not recovered (i.e., ≥ Grade 1) from adverse events due to agents previously administered; NOTE: Subjects with ≤ Grade 2 neuropathy or alopecia of any grade are an exception.
- Prior chemotherapy within 3 weeks, prior targeted small molecule therapy or radiation therapy within 2 weeks, or prior anti-cancer monoclonal antibody for direct anti-neoplastic treatment within 3 weeks prior to day 1 of treatment.
- History or known allergic reaction to doxorubicin, cyclophosphamide, paclitaxel or carboplatin.
- For Arm 1, any prior anthracycline exposure.
- For Arm 2, prior doxorubicin exposure of > 300 mg/m2 or equivalent anthracycline exposure (i.e. epirubicin dose > 540 mg/m2).
Stage 2 Exclusion Criteria
Subjects meeting any of the criteria below may not participate in Stage 2 of the study:
- Final needle aspirate (FNA) alone to diagnose primary breast cancer.
- Excisional biopsy or lumpectomy performed prior to screening.
Surgical axillary staging procedure prior to screening; NOTE: the following procedures are permitted prior to screening:
- FNA or core biopsy of an axillary node for any subject
- Although not recommended, a pre-neoadjuvant therapy sentinel node (SN) biopsy for subjects with clinically negative axillary nodes
- Definitive radiologic evidence of metastatic disease.
- History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral ductal carcinoma in-situ (DCIS) treated with radiotherapy (NOTE: subjects with a lobular CIS (LCIS) are eligible).
- Treatment including chemotherapy, radiation, and/or targeted therapy administered for the currently diagnosed breast cancer prior to screening.
- Previous therapy with anthracyclines for any malignancy.
- History of known allergic reaction to doxorubicin or cyclophosphamide.
Overall Exclusion Criteria
Subjects meeting any of the criteria below may not participate in the study:
- Active infection requiring systemic therapy (NOTE: at discretion of investigator, subjects with uncomplicated urinary tract infections may be eligible).
- Major surgery within 3 weeks of day 1 of treatment.
- Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
- Has had diagnosis, detection or treatment of another type of cancer ≤ 2 years prior to day 1 of treatment (exceptions include basal cell or squamous cell skin cancer, or in-situ cervical cancer that has been definitively treated).
- Known hypersensitivity to the components of niraparib or the excipients.
- Prior treatment with any PARP inhibitor.
- Has received any other investigational agents within 4 weeks of day 1 of treatment or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to day 1 of treatment.
- Has a known history of Human Immunodeficiency Virus (HIV) or known acquired immunodeficiency disorder (AIDS).
- Known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
- Poor medical risk as evidenced by uncontrolled intercurrent illness including, but not limited to, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator.
- Received a transfusion (platelets or red blood cells) ≤ 4 weeks of day 1 of treatment.
- Subject has a condition (such as transfusion dependent anemia or thrombocytopenia) that might confound the results of the study or interfere with the subject's participation for the full duration of the study treatment or that makes it not in the best interest of the subject to participate.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Nem véletlenszerű
- Beavatkozó modell: Szekvenciális hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: Stage 1 Arm 1
Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles, followed by AC IV every 21 days
|
IV
IV
Oral tablet
Más nevek:
Injection
|
Kísérleti: Stage 1 Arm 2
Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
|
IV
IV
Oral tablet
Más nevek:
|
Kísérleti: Stage 1 Arm 3
Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, 15, and 22 every 28 days
|
IV
Oral tablet
Más nevek:
|
Kísérleti: Stage 1 Arm 4
Niraparib 100 mg orally once daily, Paclitaxel IV Days 1, 8, and 15 every 21 days and carboplatin IV every 21 days
|
IV
IV
Oral tablet
Más nevek:
|
Kísérleti: Stage 2 Arm 1
Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 14 days with pegfilgrastim (or biosimilar) for 4 cycles
|
IV
IV
Oral tablet
Más nevek:
Injection
|
Kísérleti: Stage 2 Arm 2
Niraparib 100 mg orally once daily, Doxorubicin and Cyclophosphamide (AC) IV every 21 days
|
IV
IV
Oral tablet
Más nevek:
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Stage 1 - Evaluate dose-limiting toxicities (DLT) separately for Arms 1, 2, 3, and 4 and establish recommended Stage 2 dose of chemotherapy in combination with niraparib
Időkeret: up to 28 days
|
The DLT variable will be determined for each subject as a binary variability indicating whether or not subject experienced a protocol-defined DLT.
|
up to 28 days
|
Stage 2 - Assess clinically significant toxicities separately for Arms 1 and 2 after RS2D of niraparib is determined.
Időkeret: up to 84 days
|
The clinically significant toxicity variable will be determined for each subject as a binary variable indicating whether or not the subject experienced a niraparib-related dose delay of at least 28 days or a Grade 3 or higher niraparib-related non-hematologic toxicity.
|
up to 84 days
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Stage 1 - Objective response rate (ORR)
Időkeret: up to 30 days post-treatment discontinuation
|
Objective response will be determined for each subject in Stage 1 as a binary variable indicating whether or not the subject achieved a best overall response of CR or PR
|
up to 30 days post-treatment discontinuation
|
Stage 1 - Duration of response (DoR)
Időkeret: up to 5 years post-treatment discontinuation
|
Duration of Response (DoR) will be determined for subjects in Stage 1 who experience a PR or better and is defined as the duration of time from the first assessment that determined a CR or PR to the date of the first occurrence of progressive disease or death.
|
up to 5 years post-treatment discontinuation
|
Stage 1 - Clinical benefit rate (CBR)
Időkeret: up to 30 days post-treatment discontinuation
|
Clinical benefit will be determined for each subject in Stage 1 as a binary variable indicating whether or not the subject achieved a best overall response of CR, PR, or SD
|
up to 30 days post-treatment discontinuation
|
Stage 1 - Progression free survival (PFS)
Időkeret: up to 5 years post-treatment discontinuation
|
PFS will be determined for all subjects in Stage 1 and is defined as the duration of time from enrollment to the first occurrence of either progressive disease or death.
|
up to 5 years post-treatment discontinuation
|
Stage 1 - Overall survival (OS)
Időkeret: up to 5 years post-treatment discontinuation
|
Overall survival is defined as the duration of time from enrollment to the date of death from any cause.
|
up to 5 years post-treatment discontinuation
|
Stage 1 - Cumulative incidence of secondary malignancies including MDS
Időkeret: up to 5 years post-treatment discontinuation
|
Secondary malignancies (including MDS) will be defined as a time to event endpoint and will be calculated from the date of enrollment.
|
up to 5 years post-treatment discontinuation
|
Stage 1 - Overall safety profile - Adverse Events of Special Interest (AESIs)
Időkeret: up to 30 days post-treatment discontinuation
|
The AESI variable will be determined for each subject as a binary variability indicating whether or not subject experienced a protocol-defined AESI.
|
up to 30 days post-treatment discontinuation
|
Stage 1 - Overall safety profile - Adverse Events (AEs)
Időkeret: up to 30 days post-treatment discontinuation
|
The AE variable will be determined for each subject as a binary variability indicating whether or not subject experienced an AE per CTCAE V5.0.
|
up to 30 days post-treatment discontinuation
|
Stage 1 - Overall safety profile - Death on Study Therapy
Időkeret: up to 30 days post-treatment discontinuation
|
The death of study therapy variable will be determined for each subject as a binary variability indicating whether or not subject experienced a Grade 5 event.
|
up to 30 days post-treatment discontinuation
|
Stage 1 - Overall safety profile - Complete Blood Count with Differential (CBCD)
Időkeret: up to 30 days post-treatment discontinuation
|
The CBCD variable will be collected quantitatively for each subject.
|
up to 30 days post-treatment discontinuation
|
Stage 1 - Overall safety profile - Comprehensive Metabolic Profile (CMP)
Időkeret: up to 30 days post-treatment discontinuation
|
The CMP variable will be collected quantitatively for each subject.
|
up to 30 days post-treatment discontinuation
|
Stage 2 - Pathologic complete response (pCR)
Időkeret: up to 4 weeks post-surgery
|
Pathologic complete response (pCR) will be determined for each subject in Stage 2 as a binary variable indicating whether the subject experiences a pCR to neoadjuvant therapy.
|
up to 4 weeks post-surgery
|
Stage 2 - Clinical complete response (cCR)
Időkeret: up to 4 weeks post-surgery
|
Clinical complete response (cCR) will be determined for each subject in Stage 2 as a binary variable indicating whether the subject experiences a cCR to neoadjuvant therapy.
|
up to 4 weeks post-surgery
|
Stage 2 - Relapse-free survival
Időkeret: up to 5 years post-treatment discontinuation
|
RFS will be determined for all subjects in Stage 2 and is defined as the duration of time from enrollment to the first occurrence of either disease progression prior to surgery, disease relapse after surgery, or death.
|
up to 5 years post-treatment discontinuation
|
Stage 2 - Overall survival
Időkeret: up to 5 years post-treatment discontinuation
|
Overall survival is defined as the duration of time from enrollment to the date of death from any cause.
|
up to 5 years post-treatment discontinuation
|
Stage 2 - Cumulative incidence of secondary malignancies including MDS
Időkeret: up to 5 years post-treatment discontinuation
|
Secondary malignancies (including MDS) will be defined as a time to event endpoint and will be calculated from the date of enrollment.
|
up to 5 years post-treatment discontinuation
|
Stage 2 - Overall safety profile - Adverse Events of Special Interest (AESIs)
Időkeret: up to 4 weeks post-surgery
|
The AESI variable will be determined for each subject as a binary variability indicating whether or not subject experienced a protocol-defined AESI.
|
up to 4 weeks post-surgery
|
Stage 2 - Overall safety profile - Adverse Events (AEs)
Időkeret: up to 4 weeks post-surgery
|
The AE variable will be determined for each subject as a binary variability indicating whether or not subject experienced an AE per CTCAE V5.0.
|
up to 4 weeks post-surgery
|
Stage 2 - Overall safety profile - Serious Adverse Events (SAEs)
Időkeret: up to 4 weeks post-surgery
|
The SAE variable will be determined for each subject as a binary variability indicating whether or not subject experienced a protocol-defined SAE.
|
up to 4 weeks post-surgery
|
Stage 2 - Overall safety profile - Death on Study Therapy
Időkeret: up to 4 weeks post-surgery
|
The death of study therapy variable will be determined for each subject as a binary variability indicating whether or not subject experienced a Grade 5 event.
|
up to 4 weeks post-surgery
|
Stage 2 - Overall safety profile - Complete Blood Count with Differential (CBCD)
Időkeret: up to 4 weeks post-surgery
|
The CBCD variable will be collected quantitatively for each subject.
|
up to 4 weeks post-surgery
|
Stage 2 - Overall safety profile - Comprehensive Metabolic Profile (CMP)
Időkeret: up to 4 weeks post-surgery
|
The CMP variable will be collected quantitatively for each subject.
|
up to 4 weeks post-surgery
|
Együttműködők és nyomozók
Együttműködők
Nyomozók
- Kutatásvezető: Antoinette Tan, MD, Wake Forest University Health Sciences
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Várható)
Elsődleges befejezés (Várható)
A tanulmány befejezése (Várható)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- Bőrbetegségek
- Neoplazmák
- Neoplazmák webhelyenként
- Mellbetegségek
- Mellrák neoplazmák
- A gyógyszerek élettani hatásai
- A farmakológiai hatás molekuláris mechanizmusai
- Enzim gátlók
- Reumaellenes szerek
- Antineoplasztikus szerek
- Immunszuppresszív szerek
- Immunológiai tényezők
- Tubulin modulátorok
- Antimitotikus szerek
- Mitózis modulátorok
- Daganatellenes szerek, alkilező
- Alkilező szerek
- Mieloablatív agonisták
- Daganatellenes szerek, fitogén
- Topoizomeráz II inhibitorok
- Topoizomeráz gátlók
- Poli(ADP-ribóz) polimeráz inhibitorok
- Antibiotikumok, daganatellenes szerek
- Ciklofoszfamid
- Carboplatin
- Paclitaxel
- Doxorubicin
- Niraparib
Egyéb vizsgálati azonosító számok
- LCI-BRE-MTN-NIR-001
- 00048055 (Egyéb azonosító: Advarra IRB)
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Mellrák
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Még nincs toborzásAnatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | Korai stádiumú emlőkarcinóma | Anatómiai Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Egyesült Államok
-
University of Southern CaliforniaNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | Invazív emlőkarcinómaEgyesült Államok
-
National Cancer Institute (NCI)Aktív, nem toborzóRosszindulatú szilárd daganat | Anatómiai Stage III Breast Cancer AJCC v8 | Anatómiai Stage IV Breast Cancer AJCC v8 | Invazív emlőkarcinóma | Mell adenokarcinómaEgyesült Államok
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institute on Aging (NIA)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Mayo ClinicNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Fred Hutchinson Cancer CenterMég nincs toborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)BefejezveVékonybél adenokarcinóma | III. stádiumú vékonybél-adenokarcinóma AJCC v8 | IIIA stádiumú vékonybél adenokarcinóma AJCC v8 | IIIB stádiumú vékonybél adenokarcinóma AJCC v8 | IV. stádiumú vékonybél adenokarcinóma AJCC v8 | Vater adenokarcinóma ampulla | Stage III Ampull of Vater Cancer AJCC v8 | Stage... és egyéb feltételekEgyesült Államok
-
City of Hope Medical CenterNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | HER2-negatív emlőkarcinómaEgyesült Államok
Klinikai vizsgálatok a Carboplatin
-
Instituto Nacional de Cancerologia de MexicoToborzásTüdőrák | Sarcopenia | ToxicitásMexikó
-
James ElderBefejezveFelnőttkori anaplasztikus asztrocitóma | Felnőttkori anaplasztikus oligodendroglioma | Ismétlődő felnőttkori agydaganatEgyesült Államok
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)BefejezveIsmétlődő nem kissejtes tüdőrák | IV. stádiumú nem kissejtes tüdőrákEgyesült Államok
-
Northwestern UniversityEisai Inc.IsmeretlenFérfi mellrák | II. stádiumú mellrák | IIIA stádiumú mellrák | IIIB stádiumú mellrák | Háromszoros negatív mellrák | IA stádiumú mellrák | IB stádiumú mellrák | IIIC stádiumú mellrák | Ösztrogénreceptor-negatív emlőrák | Progeszteron-receptor-negatív emlőrák | HER2-negatív emlőrákEgyesült Államok
-
National Cancer Institute (NCI)Gynecologic Oncology GroupBefejezvePetevezető rák | Ovarian Clear Cell Cystadenocarcinoma | Petefészek endometrioid adenokarcinóma | Petefészek savós cisztadenokarcinóma | Elsődleges peritoneális üregrák | Brenner-daganat | Ismétlődő petefészek-hámrák | Petefészek mucinosus cisztadenokarcinóma | Petefészek vegyes epiteliális karcinóma | Differenciálatlan...Egyesült Államok
-
Shanghai General Hospital, Shanghai Jiao Tong University...IsmeretlenKasztráció-rezisztens prosztatarák
-
Heath SkinnerToborzásOropharynx rákEgyesült Államok
-
National Cancer Institute (NCI)BefejezveMeghatározatlan felnőttkori szilárd daganat, protokoll specifikusEgyesült Államok
-
Jonsson Comprehensive Cancer CenterTetraLogic Pharmaceuticals; California Institute for Regenerative Medicine (CIRM); Alpha Stem Cell Clinic (ASCC)VisszavontIsmétlődő petevezető karcinóma | Ismétlődő petefészek-karcinóma | Ismétlődő primer peritoneális karcinóma | Elsődleges peritoneális magas fokú savós adenokarcinóma | Magas fokú petefészek savós adenokarcinóma | Magas fokú petevezeték savós adenokarcinómaEgyesült Államok
-
Sun Yat-sen UniversityShenzhen People's Hospital; Sixth Affiliated Hospital, Sun Yat-sen University; Dongguan... és más munkatársakMég nincs toborzás2 éves betegségmentes túlélésKína